5/16
04:15 pm
nbtx
Voting Rights and Shares Capital of the Company
Low
Report
Voting Rights and Shares Capital of the Company
5/15
04:20 pm
nbtx
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 [Yahoo! Finance]
Low
Report
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 [Yahoo! Finance]
5/15
04:15 pm
nbtx
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
Low
Report
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
5/14
04:15 pm
nbtx
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
Low
Report
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
4/30
07:54 am
nbtx
Nanobiotix S.A. (NASDAQ: NBTX) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Nanobiotix S.A. (NASDAQ: NBTX) had its "buy" rating re-affirmed by analysts at HC Wainwright.
4/25
03:39 pm
nbtx
Nanobiotix reports FY results [Seeking Alpha]
Low
Report
Nanobiotix reports FY results [Seeking Alpha]
4/24
04:46 pm
nbtx
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results [Yahoo! Finance]
4/24
04:40 pm
nbtx
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Low
Report
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
4/17
04:15 pm
nbtx
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
Low
Report
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
4/10
04:15 pm
nbtx
Voting Rights and Shares Capital of the Company
Medium
Report
Voting Rights and Shares Capital of the Company
4/2
04:15 pm
nbtx
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Low
Report
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation